These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7306924)

  • 41. The effect of tamoxifen on plasma growth hormone and prolactin in postmenopausal women with advanced breast cancer.
    Paterson AG; Turkes A; Groom GV; Webster DJ
    Eur J Cancer Clin Oncol; 1983 Jul; 19(7):919-22. PubMed ID: 6684048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nyctohemeral changes in plasma prolactin levels and their relationship to breast cancer risk.
    Wang DY; Sturzaker HE; Kwa HG; Verhofstad F; Hayward JL; Bulbrook RD
    Int J Cancer; 1984 May; 33(5):629-32. PubMed ID: 6724738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peptide and steroid hormone levels in pre- and postmenopausal breast carcinoma.
    Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH
    Neoplasma; 1987; 34(1):95-9. PubMed ID: 3104809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Possible linkage between the ability to change the period (tau) of the prolactin and cortisol rhythms in women and breast cancer risk.
    Lewy H; Haus E; Ashkenazi IE
    Chronobiol Int; 2007; 24(2):365-81. PubMed ID: 17453854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma prolactin and its relationship to risk factors in human breast cancer.
    Kwa HG; Cleton F; de Jong-Bakker M; Bulbrook RD; Hayward JL; Wang DY
    Int J Cancer; 1976 Apr; 17(4):441-7. PubMed ID: 945228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Correlations between PRL and 17-beta-E in human breast cancer].
    Larrad Jiménez A; Ruiz-Tartas A; Zapatero Gaviria J; López Lazareno N
    Rev Esp Oncol; 1984; 31(2):279-87. PubMed ID: 6549590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolactin and breast cancer risk.
    Ingram DM; Nottage EM; Roberts AN
    Med J Aust; 1990 Oct; 153(8):469-73. PubMed ID: 2215338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between changes in prolactin and melatonin serum levels after radical mastectomy.
    Lissoni P; Paolorossi F; Barni S; Tancini G; Crispino S; Rovelli F; Ferri L; Esposti G; Esposti D; Fraschini F
    Tumori; 1987 Jun; 73(3):263-7. PubMed ID: 3603722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer.
    Love RR; Rose DR; Surawicz TS; Newcomb PA
    Cancer; 1991 Sep; 68(6):1401-5. PubMed ID: 1873792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating levels of prolactin in human breast cancer.
    Sheth NA; Ranadive KJ; Suraiya JN; Sheth AR
    Br J Cancer; 1975 Aug; 32(2):160-7. PubMed ID: 2274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hormone concentrations in postmenopausal patients with breast cancer.
    Jones MK; Ramsay ID; Booth M; Collins WP
    Clin Oncol; 1977 Jun; 3(2):177-81. PubMed ID: 872471
    [No Abstract]   [Full Text] [Related]  

  • 52. Plasma prolactin levels and age in a female population: relation to breast cancer.
    Bulbrook RD; Wang DY; Hayward JL; Kwa HG; Cleton F
    Int J Cancer; 1981 Jul; 28(1):43-5. PubMed ID: 7309281
    [No Abstract]   [Full Text] [Related]  

  • 53. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer.
    Holtkamp W; Nagel GA; Wander HE; Rauschecker HF; von Heyden D
    Int J Cancer; 1984 Sep; 34(3):323-8. PubMed ID: 6480153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients.
    Mandalà M; Lissoni P; Ferretti G; Rocca A; Torri V; Moro C; Curigliano G; Barni S
    Oncology; 2002; 63(4):370-7. PubMed ID: 12417792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormalities in evening plasma prolactin levels in nulliparous women with benign or malignant breast disease.
    Tarquini A; di Martino L; Malloci A; Kwa HG; van der Gugten AA; Bulbrook RD; Wang DY
    Int J Cancer; 1978 Dec; 22(6):687-90. PubMed ID: 721323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Plasma levels of prolactin in women with dysplasia and tumors of the breast (fibroadenoma and carcinoma of the breast)].
    Iturburu Belmonte IM; Basáñez Amuchastegui A; Jiménez Jiménez E; López de Tejada Cabeza I; Goicoechea García J; Méndez Martín J
    Rev Quir Esp; 1988; 15(1):17-21. PubMed ID: 3153353
    [No Abstract]   [Full Text] [Related]  

  • 57. Adrenal function in early and metastatic breast cancer: dexamethasone suppression of plasma cortisol.
    Drafta DS; Stroe E; Schindler EE; Teodosiu T; Gozariu L; Drafta D
    Endocrinologie; 1981; 19(2):115-21. PubMed ID: 6789444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of serum prolactin levels in advanced breast cancer.
    Dowsett M; McGarrick GE; Harris AL; Coombes RC; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 Jun; 47(6):763-9. PubMed ID: 6860546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of reserpine on prolactin levels and incidence of breast cancer in postmenopausal women.
    Ross RK; Paganini-Hill A; Krailo MD; Gerkins VR; Henderson BE; Pike MC
    Cancer Res; 1984 Jul; 44(7):3106-8. PubMed ID: 6722826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of mastectomy versus mastectomy plus adjuvant ovariectomy on prolactin response to TRH in breast cancer.
    Ayala D; Lissoni P; Archili C; Barni S; Roveda G; Giacomelli M; Bissi A
    J Biol Regul Homeost Agents; 1990; 4(4):150-2. PubMed ID: 2128988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.